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The scope of central tolerance is determined by 
the  recognition  of  self-antigens  presented  by 
various APCs in the thymus. The thymic me-
dulla is the major but not exclusive site of central 
tolerance induction (McCaughtry et al., 2008). 
The complexity of this process with regard to 
the composition and role of distinct APC types, 
and the sets of self-antigens displayed has only 
recently become apparent. Self-antigens can be 
supplied by the proteome of residential epithe-
lial cells (i.e., cortical and medullary thymic epi-
thelial cells [mTECs]) and BM-derived APCs 
(i.e., DCs, macrophages [M], and B cells). In 
addition, self-antigens from the periphery can 
reach the thymus medulla via the blood stream 
or be imported via immigrating antigen-laden 
DCs (Klein et al., 2001; Bonasio et al., 2006; Li 
et al., 2009). Among these different self-antigen 
pools, the array of promiscuously expressed tis-
sue-restricted self-antigens by mTECs is of par-
ticular interest, because it preempts the peripheral 
self. Qualitative or quantitative alterations of this 
antigen pool predispose to organ-specific auto-
immunity. How central tolerance to these anti-
gens is achieved is closely connected to the 
questions of which APCs present these antigens 
and which processing pathways are involved 
(Klein and Kyewski, 2000).
Previous studies addressing these issues have 
been limited to broadly expressed self-antigens 
(i.e., E; Humblet et al., 1994), or neo–self-anti-
gens driven by promoters resulting in expression 
in a major subset of mTECs (i.e., the Aire pro-
moter; Aschenbrenner et al., 2007) or in more 
restricted expression, e.g., the rat insulin pro-
moter (Zhang et al., 2003; Gallegos and Bevan, 
2004; Zehn and Bevan, 2006). In case of the   
latter transgenes, it remained however unclear 
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Central tolerance is shaped by the array of self-antigens expressed and presented by vari-
ous types of thymic antigen-presenting cells (APCs). Depending on the overall signal qual-
ity and/or quantity delivered in these interactions, self-reactive thymocytes either apoptose 
or commit to the T regulatory cell lineage. The cellular and molecular complexity underly-
ing these events has only recently been appreciated. We analyzed the ex vivo presentation 
of ubiquitous or tissue-restricted self-antigens by medullary thymic epithelial cells (mTECs) 
and thymic dendritic cells (DCs), the two major APC types present in the medulla. We 
found that the ubiquitously expressed nuclear neo–self-antigen ovalbumin (OVA) was 
efficiently presented via major histocompatibility complex class II by mTECs and thymic 
DCs. However, presentation by DCs was highly dependent on antigen expression by TECs, 
and hemopoietic cells did not substitute for this antigen source. Accordingly, efficient 
deletion of OVA-specific T cells correlated with OVA expression by TECs. Notably, OVA was 
only presented by thymic but not peripheral DCs. We further demonstrate that thymic DCs 
are constitutively provided in situ with cytosolic as well as membrane-bound mTEC-derived 
proteins. The subset of DCs displaying transferred proteins was enriched in activated DCs, 
with these cells being most efficient in presenting TEC-derived antigens. These data pro-
vide evidence for a unique, constitutive, and unidirectional transfer of self-antigens within 
the thymic microenvironment, thus broadening the cellular base for tolerance induction 
toward promiscuously expressed tissue antigens.
© 2009 Koble and Kyewski  This article is distributed under the terms of an At-
tribution–Noncommercial–Share Alike–No Mirror Sites license for the first six 
months  after  the  publication  date  (see  http://www.jem.org/misc/terms.shtml).   
After six months it is available under a Creative Commons License (Attribution–
Noncommercial–Share Alike 3.0 Unported license, as described at http://creative-
commons.org/licenses/by-nc-sa/3.0/).
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only 10–20% express CD8 (Vremec et al., 1992; den Haan 
et al., 2000). Hence, we separately assessed CD8pos and 
CD8neg DCs from the thymus and spleen. Enrichment of 
neither subset rescued splenic OVA presentation, arguing 
against variable DC subset composition to account for the 
observed interorgan differences (Fig. S2).
These results suggest that the efficient presentation of the 
ubiquitously expressed self-antigen OVA by thymic DCs ei-
ther reflects a property of a specialized thymic DC subset (if 
presented autonomously), or that antigen is provided specifi-
cally within the medullary microenvironment, i.e., by trans-
fer from hemopoietic cells or TECs. To distinguish between 
these alternatives, we generated BM chimeras in which ei-
ther  BM-derived  APCs  or  TECs  expressed  OVA  exclu-
sively. Remarkably, efficient OVA presentation by thymic 
DCs  was  observed  only  when  OVA  was  expressed  by   
radio-resistant host cells. In contrast, OVA presentation by 
thymic DCs was inefficient when DCs themselves (and other   
hemopoietic cells), but not radioresistant stromal cells, were   
transgenic for Ld-nOVA (Fig. 2 A). At the same time, OVA 
presentation by mTECs was strictly dependent on endoge-
nous expression (Fig. 2 A). However, antigen presentation 
was lower in mTECs isolated from chimeras as compared 
with WT, possibly as a consequence of radiation damage. 
Conversely, DCs isolated from BALB/c → BALB/c chime-
ras induced higher TC activation than those from nonma-
nipulated mice. A possible explanation, not further explored 
in this report, is the generation of cross-reactive epitopes by 
radiation, which is not without precedent (Reits et al., 2006). 
Presentation by splenic DCs remained low, irrespective of 
the type of chimera (Fig. 2 A). These data show that nuclear 
OVA is autonomously presented to CD4+ TCs by mTECs, 
whereas its presentation by thymic DCs mostly relies on   
antigen transfer from radio-resistant TECs, but not from   
hemopoietic cells. A similar efficient transfer mechanism ob-
viously does not exist in the microenvironment of the spleen 
and lymph nodes, at least at the level of resolution attained 
here. The differences in ex vivo presentation of OVA were 
also reflected at the level of TC selection. Deletion of OVA-
specific DO11.10 TCs was most efficient when OVA was 
expressed by radio-resistant TECs irrespective of additional 
OVA expression in BM-derived cells (Fig. 2, B and C). The 
lower but perceptible degree of deletion by OVA-expressing 
BM cells indicates that OVA does access MHC class II on 
DCs, possibly via the secretory pathway followed by endo-
cytosis, a route that has not been strictly excluded by the 
study of Kawahata et al. (2002).
Ex vivo presentation of ectopically expressed endogenous 
TRAs by thymic APCs
To verify whether presentation of promiscuously expressed 
endogenous antigens follows the same rules as deduced from 
transgenic models (Zhang et al., 2003; Gallegos and Bevan, 
2004; Zehn and Bevan, 2006), we assessed the ex vivo   
presentation of the TRAs P1A and PLP via MHC class I 
and II, respectively.
whether the frequency of antigen-positive mTECs and the   
expression levels per cell faithfully reflected the pattern of pro-
miscuously expressed tissue-restricted antigens (TRAs). Both 
parameters are critical for T cell (TC) selection.
In this report, we analyzed ex vivo presentation of the 
two native self-antigens, P1A and proteolipid protein (PLP). 
The tumor rejection antigen P1A is a prototypic cytosolic 
TRA whose expression is tightly regulated and only detect-
able in male germ cells and rare mTECs (Derbinski et al., 
2001). PLP, an oligodendrocyte-specific myelin protein, is 
strongly expressed in mTECs and weakly expressed in thymic 
DCs (Derbinski et al., 2001). Moreover, we wanted to delin-
eate the relative contribution of thymic APC types to toler-
ance when antigen expression is not confined to a particular 
cell type. To this end, we chose the neo–self-antigen OVA, 
expressed ubiquitously and targeted specifically to the nucleus 
(Kawahata et al., 2002).
We found both thymic DCs and mTECs to present these 
self-antigens ex vivo and in vivo. Efficient presentation by DCs, 
however, was contingent on antigen provision by TECs irre-
spective of their subcellular localization or expression pattern. 
This efficient self-antigen transfer, which apparently is unique 
to the thymus, broadens the cellular base of self-tolerance and 
thus enhances its efficacy.
RESULTS AND DISCUSSION
Ex vivo presentation of an ubiquitous, nuclear self-antigen 
by thymic APCs
We  chose  to  analyze  presentation  of  the  neo–self-antigen 
OVA driven by the ubiquitous MHC class I (Ld) promotor. 
In contrast to previous studies that mainly focused on soluble 
(Klein et al., 2001) or membrane-bound neo–self-antigens 
(Zhang et al., 2003; Gallegos and Bevan, 2004; Zehn and 
Bevan, 2006; Aschenbrenner et al., 2007), in this case a nuclear 
localization sequence targets OVA protein to the nucleus, 
thus representing self-antigens of the nuclear compartment 
(Kawahata et al., 2002).
Ex vivo OVA presentation was assayed by co-culture   
of purified APCs from the thymus, spleen, and mesenteric 
lymph nodes of Ld-nOVA mice together with naive DO11.10 
CD4+ TCs expressing a TCR specific for the OVA peptide 
323–339 in conjunction with I-Ad (Murphy et al., 1990; 
Kawahata et al., 2002). Thymic DCs displayed the most effi-
cient presentation followed by mTECs, whereas splenic and 
lymph node–derived DCs induced a 10- to 40-fold lower 
proliferation (Fig. 1 A). At the same time, all four APC pop-
ulations showed comparable antigen presentation on a per 
cell basis when loaded with exogenous peptide, excluding 
overall presentation competence to account for the observed 
differences (Fig. S1 A). Moreover, thymic and splenic DCs 
displayed similar OVA expression at the RNA level (Fig. 1 B). 
One reason for the remarkable difference in efficacy of OVA 
presentation between thymic and peripheral DCs could re-
side in their respective composition. 60–90% of thymic DCs 
belong to the CD8pos subset, which was shown to be most 
efficient in cross-presentation, whereas among splenic DCs, JEM VOL. 206, July 6, 2009  1507
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thymic DCs in the RIP-mOVA mouse model. In contrast, 
TECs were sufficient to delete CD4+ TCs specific for solu-
ble human C-reactive protein (Klein et al., 1998, 2001), and 
mTECs were capable of deleting CD4+ TCs specific for mem-
brane-bound hemagglutinin (Aschenbrenner et al., 2007).
We chose PLP, a myelin sheath component, to assess 
MHC class II–restricted ex vivo presentation. PLP is promis-
cuously expressed by both cortical thymic epithelial cells and 
mTECs and at marginal levels in DCs (Fig. 1 F), with 1–3% 
of all mTECs expressing the PLP protein (Derbinski et al., 
2001). Presentation of PLP was assayed using a CD4+ TC 
line specific for the epitope 239–250 in the context of I-Ab. 
Importantly, this epitope is present in the DM20 isoform of 
PLP, which is predominantly expressed in the thymus (Klein 
et al., 2000; Derbinski et al., 2001). In line with previous re-
sults, thymic DCs efficiently presented PLP (Fig. 1 E). In 
contrast, neither mTECs, including the mature subset, nor 
splenic DCs induced proliferation above background levels. 
The lack of presentation by mature mTECs was unexpected 
The tumor antigen P1A is only expressed in mTECs but 
not in thymic or splenic DCs (Fig. 1 D), whereby 1–3% of 
mTECs express P1A at the protein level (Derbinski et al., 
2001). Ex vivo presentation of P1A was assayed by prolifera-
tion of freshly isolated naive CD8+ TCs expressing a trans-
genic TCR specific for the P1A epitope 35–43. Again, thymic 
DCs proved to be most efficient (Fig. 1 C), pointing toward 
cross-presentation  of  mTEC-derived  P1A,  whereas  direct 
presentation by mTECs was clearly weaker and only revealed 
by isolating the mature mTEC subset (Fig. S3). No significant 
proliferation was induced by splenic DCs. Again, this pattern 
could not be explained by differences in the presentation 
competence of the various APC populations (Fig. S1 B).
A  previous  report  on  in  vivo  deletion  of  autoreactive 
OVA-specific CD8+ and CD4+ TCs showed differences in 
the requirement for cross-presentation (Gallegos and Bevan, 
2004). Although both mTECs and DCs were able to delete 
MHC class I–restricted OT-1 cells, deletion of MHC class 
II–restricted OT-2 cells required OVA cross-presentation by 
Figure 1.  Efficient presentation of TEC-derived self-antigens by thymic DCs. mTECs and DCs from the thymus (Thy-DC), spleen (Sp-DC), and 
lymph nodes (LN-DC) of (A) Ld-nOVA, (C) BALB/c, or (E) C57BL/6 mice, respectively, were co-cultured for 3 d with antigen-specific TCs. Presentation of OVA 
(A), P1A (C), and PLP (E) was assessed by antigen-specific proliferation of naive DO11.10 CD4+ TCs, P1A-TCR transgenic CD8+ TCs, or the PLP-specific TC 
line TPLP-15-5-2. Shown are the triplicate mean values ± SD of one representative of at least two experiments performed. Transcription of (B) OVA,  
(D) P1A, and (F) DM20 by the indicated cell populations was evaluated by quantitative (B and F) or semiquantitative (D) PCR analysis. Expression levels were 
normalized to HPRT/Ubiquitin (B) or -actin (D and F). Error bars in B and F indicate the SD of triplicates of the same cDNA preparation.1508 SELF-ANTIGEN TRANSFER WITHIN THE THYMIC MEDULLA | Koble and Kyewski
given the strong mRNA signal and detectable protein ex-
pression (Derbinski et al., 2001). Possible explanations are a 
lower PLP protein expression and stability and/or inefficient 
processing by mTECs when compared with P1A. Irrespec-
tive of these considerations, PLP expression and presentation 
by mTECs and DCs are inversely correlated, which is indica-
tive of antigen transfer from TECs to DCs rather than auton-
omous presentation by DCs. This interpretation is indirectly 
supported by the lack of PLP presentation by splenic DCs.
Thus, presentation of these two TRAs, P1A and PLP, 
follows similar rules as shown for Ld-nOVA. Which features 
of the medullary microenvironment might account for the 
efficient transfer of self-antigens?
Transfer routes from mTECs to DCs
At least four mechanisms might contribute to the intercellular 
transfer of proteins of different subcellular compartments: exo-
some transfer, uptake of apoptotic bodies, membrane exchange 
(“nibbling”), and gap junctions (Albert et al., 1998; Harshyne 
et al., 2001; Thery et al., 2002; Neijssen et al., 2005). The most 
direct way to confer MHC-restricted antigen presentation onto 
another cell is the exchange of surface membrane–bound pep-
tide–MHC complexes. We addressed this option by analyzing 
the transfer of MHC class II molecules in P → F1 type chimeras, 
i.e., BALB/c → (BALB/c × C57BL/6)F1 and C57BL/6 → 
(BALB/c × C57BL/6)F1 mice. 6–8 wk after reconstitution, 
thymic DCs were isolated and analyzed for expression of host-
specific MHC haplotypes. Clearly, DCs stained for MHC class 
II molecules transcribed by radio-resistant host cells, with the 
density of expression of these “acquired” MHC molecules   
being lower than on DCs of heterozygous animals (Fig. 3, A 
and B). These results concur with a recent report describing a 
unidirectional transport of MHC class II molecules between 
thymic APCs in vitro and in vivo (Millet et al., 2008).
We next explored a second route, namely the transfer of cy-
toplasmic proteins, that either could occur via uptake of apop-
totic bodies or directed exosome traffic. To this end, we analyzed 
thymi of FoxN1-eGFP reporter mice. These mice express eGFP 
intrathymically exclusively in TECs under the control of the 
epithelium-specific FoxN1 promoter, but not in hemopoietic 
cells (Terszowski et al., 2006). Thymic DCs from this strain dis-
played a green fluorescence signal clearly above background 
level but weaker than that of TECs (Fig. 3, C and D). Interest-
ingly, the degree of eGFP staining of thymic DCs correlated with 
surface staining for epithelial cell adhesion molecule (EpCAM), 
which presumably, like MHC class II molecules, was acquired 
from TECs (Fig. 3, D and E). Expression of EpCAM on hemo-
poietic cells had previously been observed but not further   
Figure 2.  Ex vivo presentation of the nuclear neo–self-antigen OVA 
by thymic DCs and efficient deletion of DO11.10 TCs in vivo depend on 
antigen transfer from radio-resistant stromal cells. (A) Lethally irradiated 
BALB/c WT or Ld-nOVA transgenic mice were reconstituted with TC-depleted 
BM cells of the indicated donor strains. After 5–8 wk, CD11c+ DCs of the 
thymus (Thy-DC) and spleen (Sp-DC) and mTECs, respectively, were isolated 
and co-cultured with DO11.10 CD4+ TCs. OVA presentation was assessed by 
antigen-specific proliferation of TCs. Bars represent threefold titration steps 
of the indicated APC population ranging from 3 × 105–103 cells/well. Shown 
are the triplicate mean values ± SD of one representative of two or more 
experiments performed. (B) 5–6 wk after reconstitution, the number of total 
CD4 single-positive and DO11.10 clonotype-specific CD4 single-positive thy-
mocytes was assessed. Symbols represent values of 7–10 individual thymi in 
each group. *, P < 0.005. (C) FACS analysis of clonotypic DO11.10 CD4 single-
positive spleen TCs of each chimera type. Shown are overlay histograms of 
three individuals. Arrows indicate DO11.10 clonotype-specific CD4+ TCs.
 JEM VOL. 206, July 6, 2009  1509
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were enriched in cells expressing CD80, CD86, CD103, and 
MHC class II, indicative of a mature phenotype (Fig. 4 and 
Fig. S4). At the same time, this subset was devoid of CD11b- 
and F4/80-positive cells, i.e., monocytes/M. Most markers 
showed  a  monophasic  distribution  with  the  exception  of 
CD103, CD24, and mPDCA1, indicating further heteroge-
neity among this DC subset.
Next we asked whether TEC-tainted DCs were also en-
riched in DCs cross-presenting TEC-derived self-antigens, 
explored (Borkowski et al., 1996). The costaining of eGFP and 
EpCAM by a subset of DCs implies that the same cells acquire 
TEC-derived membrane receptors and cytoplasmic proteins.
Phenotype and function of “TEC-tainted” DCs
Given the correlation between EpCAM and eGFP expres-
sion, we used these surrogate markers to further characterize 
this DC subset with respect to phenotype and function.   
Assessing a panel of markers, eGFP/EpCAM-positive DCs 
Figure 3.  Cotransfer of membrane-bound and cytoplasmic proteins from epithelial cells marks DCs with efficient cross-presentation.  
(A and B) Lethally irradiated CB6/F1 mice were reconstituted with either BALB/c (A) or C57BL/6 (B) TC-depleted BM. After 6 wk, low density TSCs were 
enriched by Nycodenz density gradient centrifugation. Cells were stained with mAb against CD11c, EpCAM, and the parental MHC class II haplotypes I-Ab 
and I-Ad. Thymic DCs were defined as CD11chigh EpCAMintermediate cells. Expression of the respective host-specific MHC haplotype by thymic DCs is displayed 
as shaded histograms, whereas lines represent expression of the indicated haplotypes by C57BL/6 (solid), CB6/F1 (dashed), or BALB/c (dotted) thymic DCs.  
(C) EGFP-containing cells are detectable within the CD11c+ thymic DC population of FoxN1-eGFP mice. Thymic CD11c+ cells were preenriched using MACS 
technology and analyzed by flow cytometry, excluding autofluorescent cells. (D) EGFP-expressing TECs are distinguishable from eGFP-containing thymic 
DCs on the basis of differential CD11c expression, as shown by flow-cytometric analysis of single-cell suspensions. Cells were isolated and pooled from 
five FoxN1-eGFP thymi. (E) EpCAM expression of FoxN1-eGFP CD11c+ thymic DCs correlates with eGFP fluorescence intensity, as shown for CD45, non-
autofluorescent cells. (F) EpCAM-expressing CD11c+ thymic DCs (Thy-DC) present TEC-derived OVA most efficiently. CD11c+ thymic DCs of Ld-nOVA mice 
were enriched according to differential CD11c and EpCAM coexpression, resulting in the indicated subpopulations of ≥99% purity. CD11c+ splenic DCs 
(Sp-DC) were enriched by magnetic separation (purity ≥ 90%). OVA presentation was assessed by proliferation of OVA-specific DO11.10 CD4+ TCs after a 
3-d co-culture period. Shown are the means of triplicates ± SD. Each figure (C–F) is representative of two to six independent experiments.1510 SELF-ANTIGEN TRANSFER WITHIN THE THYMIC MEDULLA | Koble and Kyewski
We consider this autonomous presentation of OVA by mTECs 
to be most likely caused by constitutive macroautophagy in 
TECs (Nedjic et al., 2008), which, in addition to cytosolic 
proteins, also includes nuclear self-antigens (Riedel et al., 
2008). Indeed, peptides derived from nuclear proteins can 
be eluted from MHC class II of mTECs (unpublished data). 
Several explanations could account for the fact that OVA-
expressing hemopoietic cells (including TCs, DCs, M, and 
B cells) are poor in providing antigenic material for cross-
presentation, depending on the mechanism of self-antigen 
transfer. If processed antigens were transferred, as recently 
shown in vitro (Millet et al., 2008), hemopoietic cells might 
lack the ability to generate the specific peptide–MHC class 
II complex to be transferred onto DCs (i.e., they lack con-
stitutive autophagy). If antigen were transferred in its native 
form and processing occurred in the target cell, generation 
of transfer vehicles by hemopoietic cells might be less effi-
cient than by TECs. Irrespective of these considerations, the 
observed antigen transfer could occur via membrane transfer 
of peptide–MHC complexes, exosomes, or apoptotic bodies. 
At present we cannot distinguish between these different 
e.g., Ld-nOVA. When separated on the basis of quantitative 
expression  of  EpCAM,  those  DCs  displaying  the  highest 
level showed the most efficient ex vivo presentation of OVA, 
whereas EpCAMlow expressors were relatively depleted for 
cross-presentation (Fig. 3 F). These data reveal a novel pheno-
type/function correlation: the subset of thymic DCs that 
most efficiently cross-presents TEC-derived TRA displays a 
mature phenotype and tracers indicative of recent direct in-
teractions with TECs.
Our  data  document  constitutive  cross-presentation  of 
(m)TEC-derived nuclear, cytosolic, and membrane-bound 
self-antigens by thymic DCs along with autonomous pre-
sentation by mTECs. Of particular interest are three obser-
vations. First, only TEC- but not hemopoietic cell–derived 
(nuclear) antigens are efficiently cross- presented by thymic 
DCs. Second, this antigen transfer is unidirectional (Millet   
et al., 2008). Third, the neo–self-antigen OVA, which is ex-
pressed in the nucleus under an ubiquitous promoter, is au-
tonomously presented via MHC class II only by mTECs but 
not hemopoietic APCs of the thymus or the periphery, a 
finding consistent with a previous study (Oukka et al., 1996). 
Figure 4.  EGFP-containing thymic DCs of FoxN1-eGFP mice display a mature phenotype. TSCs of FoxN1-eGFP mice were preenriched for CD11c+ 
cells using MACS technology (purity ≥ 60%). Subsequently, positively selected cells were stained for CD11c and EpCAM (Fig. 3 B) together with one addi-
tional marker and analyzed by flow cytometry. Shaded histograms indicate negative controls representing isotype control or secondary antibody stainings. 
Expression of indicated marker molecules by eGFP TSCs is displayed in red and expression by eGFP+ cells is displayed in blue. Arrows indicate marker pro-
files correlating with eGFP content. For details see Materials and methods. Each histogram is representative of one to three independent experiments.JEM VOL. 206, July 6, 2009  1511
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Cell preparation and analysis
Isolation of mouse thymic stromal cells (TSCs). TSCs were purified as 
described previously (Derbinski et al., 2001) or with the following modifica-
tions: after three rounds of collagenase digestion and one round of collagenase/
dispase digestion, thymic rosettes were pooled, washed in PBS containing 0.5% 
BSA and 5 µM EDTA, and stained with anti-CD11c microbeads (Miltenyi Bio-
tec). Subsequently, CD11c+ thymic DCs were isolated using MACS technology 
according to the manufacturer’s protocol (Miltenyi Biotec), resulting in a sus-
pension containing 90–95% CD11c+ cells. For subdivision of thymic DCs, 
CD11c-enriched TSCs were stained with various combinations of biotinylated 
anti-CD11c (HL3) and streptavidin-PE or streptavidin-allophycocyanin-Cy7 
(BD), anti–EpCAM–Alexa Fluor 647 (G8.8), anti-CD45–PE or CD45-PerCP, 
respectively (both 30-F11; BD), and anti-CD8–PE (53-6.7; BD). The TEC-
containing fraction (collagenase/dispase digestion rounds two to five) was fur-
ther enriched by MACS depletion of CD45+ hemopoietic cells using anti-CD45 
microbeads (Miltenyi Biotec), followed by staining with either anti-CDR1–
  Alexa Fluor 488 or anti-Ly51–FITC (6C3; BD), anti–EpCAM–Alexa Fluor 647 
(G8.8), and anti-CD45–PE (30-F11). After staining, cells were resuspended in 
FACS buffer containing 1 µg/ml propidium iodide to exclude dead cells. For 
subdivision of mTECs, the following combinations were used: anti-CD80–PE 
(16-10A1) or anti-KLH–PE (Ha 4/8; isotype control), anti-CD45–PerCP (30-
F11), anti-Ly51–FITC (6C3; all were obtained from BD), and anti–EpCAM–
Alexa Fluor 647 (G8.8). FcR blocking with the anti-FcR mAb 2.4G2 preceded 
all stainings. Cell sorting was performed with a cell sorter (FACSDiVa; BD). 
Autofluorescent cells were excluded from the sorted populations.
For phenotype analysis of DC subpopulations, in addition to the afore-
mentioned  reagents  the  following  antibodies  were  used:  anti-CD86–PE 
(GL1; BD), anti–MHC class II–PE I-Ad (AMS-32.1; BD), anti-CD24–PE 
I-Ad (M1/69; BD), anti-F4/80–FITC (CI:A3-1; AbD Serotec), and anti-
mPDCA1–PE (JF05-1C2.4.1; Miltenyi Biotec).
The frequency of clonotype-specific TCs was assessed by costaining 
with anti-CD4–FITC (H129.19; BD), anti-CD8–PE (53-6.7; BD), and 
biotinylated anti-DO11.10 clonotype (KJ1-26; eBioscience) antibodies, fol-
lowed by streptavidin-allophycocyanin-Cy7 (BD).
Flow cytometric measurements were performed using a FACSCalibur 
or FACSCanto II (BD). Data were collected from viable lymphocytes by 
appropriate forward and side scatter gating. Data analysis was performed with 
FlowJo software (version 6.4.1; Tree Star, Inc.).
Isolation of lymphoid cells from the spleen. Myeloid and lymphoid 
DCs from the spleen were isolated as previously described (den Haan et al., 
2000), with minor modifications. In brief, a collagenase-digested suspension 
of four to eight spleens was subjected to erythrocyte lysis and filtered through 
a 70-µm cell strainer. Cells were collected in PBS containing 0.5% BSA and 
5 µM EDTA and stained with anti-CD11c microbeads (Miltenyi Biotec). 
Subsequently, CD11c+ DCs were isolated using MACS technology accord-
ing to the manufacturer’s protocol (Miltenyi Biotec), resulting in a suspen-
sion containing 90–95% CD11c+ cells.
For isolation of TCs, spleens of one to two mice were minced into small 
pieces and passed through a metal sieve. After erythrocyte lysis, the cell sus-
pension was washed in PBS containing 0.5% BSA and 5 µM EDTA and fil-
tered through a 70-µm cell strainer. For enrichment of CD4+ TCs, cells 
were incubated with anti-CD4 (L3T4) microbeads, followed by magnetic 
separation of CD4+ cells according to manufacturer’s protocol (Miltenyi 
Biotec). CD8+ TCs were isolated by magnetic depletion of CD8 cell popu-
lations using the CD8+ T cell isolation kit (Miltenyi Biotec). For both TC-
populations, purity was ≥95%, as confirmed by flow cytrometrical analysis.
RNA preparation and cDNA synthesis
Whole-tissue RNA was isolated using DNaseI digestion on column with an 
Ultra-Turrax T8 (IKA) and the RNeasy Mini Kit (QIAGEN), or from a 
single-cell suspension with the High Pure RNA Isolation Kit (Roche). Total 
RNA (3 µg of tissue-extracted RNA or an equivalent of 105–106 single cells) 
was reverse transcribed into cDNA with Oligo(dT)20 primer and Superscript 
II RT (Invitrogen), followed by RNase H digestion (Fermentas).
modes. The fact that DCs expressing the highest amount   
of EpCAM also show the strongest GFP staining speaks in 
favor of cotransfer of cytosolic and membrane constituents 
i.e., via directed exosome trafficking or apoptotic bodies. 
However, we consider uptake of apoptotic bodies as the 
main mechanism less likely, because negative selection of au-
toreactive TCs directly interacting with mTECs (Irla et al., 
2008) should provide plenty of antigenic material, yet such a 
transfer is not observed. Moreover, the extensive transfer of 
membrane complexes between mTECs and DCs would 
comply with the similar in vivo half-life of peptide–MHC 
complexes on both cell types, which is in the range of 25 h 
(unpublished data).
Our results imply that the self-antigen repertoire specifically 
generated by mTECs is also available to DCs for presentation. 
This concurrent presentation ensures that any particular toler-
ance mode linked to a special APC type will cover the array of 
promiscuously expressed genes. Thus, mTECs have been shown 
to be more efficient in selecting T reg cells, whereas DCs 
are the better deleters (Apostolou et al., 2002; Aschenbrenner 
et al., 2007). This preference, however, is relative rather 
than absolute, because bone marrow-derived APCs can also 
generate T reg cells under contrived experimental conditions 
(Watanabe et al., 2005; Spence and Green, 2008; Wirnsberger 
et al. 2009). In this context it is worth noting that DCs interact-
ing with mTECs display a phenotype similar to intestinal DCs, 
which induce T reg cells (Coombes et al., 2007). Furthermore, 
TEC-interacting DCs are still phenotypically heterogeneous 
and include plasmacytoid- and myeloid-type DCs, both of 
which have recently been proposed to induce different subsets 
of T reg cells (Ito et al., 2008).
Our data characterize a constitutive and unidirectional 
transfer route for self-antigens between mTECs and DCs, 
which is possibly unique to the microenvironment of the 
thymic medulla. By this way, the set of tissue-restricted self-
antigens exclusively expressed by mTECs also becomes avail-
able to the second major APC type involved in TC repertoire 
selection, thus ensuring that this critical set of self-antigens is 
“double checked” for tolerance induction.
MATERIALS AND METHODS
Animals
C57BL/6, BALB/c, and CB6/F1 mice were obtained from Charles River 
Laboratories. Ld-nOVA mice (Kawahata et al., 2002) on the BALB/c back-
ground were provided by K. Yamamoto (University of Tokyo, Tokyo,     Japan) 
and were further interbred. FoxN1-eGFP mice (Terszowski et al., 2006) were 
provided by T. Boehm (Max-Planck-Institute for Immunobiology, Freiburg, 
Germany) and backcrossed for at least five generations on the BALB/c back-
ground.  DO11.10  TCR  transgenic  mice  have  been  described  previously 
(Murphy et al., 1990) and were kept as an inbred strain. TCRP1A transgenic 
mice were provided by A.-M. Schmitt-Verhulst (University of Marseille, 
Marseille, France), and were generated on a RagO/O B10.D2 background, as 
described previously (Shanker et al., 2004), and kept as an inbred strain.
All animals were kept under specific pathogen-free conditions in the 
animal facilities of the German Cancer Research Center. For preparation of 
APCs, mice of both genders were used at the age of 4–12 wk. TCR trans-
genic TCs were isolated from 12–16-wk-old mice. Animal experiments 
were approved by local authorities (Regierungspräsidium Karlsruhe, permit 
nos. DKFZ 155, DKFZ 169, DKFZ 196, and G-66/02).1512 SELF-ANTIGEN TRANSFER WITHIN THE THYMIC MEDULLA | Koble and Kyewski
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Amplification was performed in a DNA Engine Dyad ThermoCycler 
(Biozym) under standard thermal cycler conditions. Reaction products were 
separated on 1 × TAE (40 mM Tris-acetate, 1 mM EDTA) 1.5% agarose 
gels that contained 30 ng/ml ethidium bromide (Roth). PCR products were 
revealed with the Lumi-Imager F1 Workstation (Roche) or a video docu-
mentation  system  (BioVision;  Peqlab),  and  bands  were  quantified  with   
LumiAnalyst software (version 3.0; Roche) or Vision-Capture software (version 
12.9; Peqlab). For semiquantitative PCR, cDNA preparations were normal-
ized to -actin expression before testing expression of the gene of interest.
Quantitative PCR
Real-time PCR reactions were performed in a final volume of 25 µl with 
optimal concentrations of forward and reverse primers (50–900 nM) using 
the qPCR core kit for SybrGreen I (Eurogentec) containing Hot GoldStar 
polymerase and Uracil-N-Glycosylase. Probes were used at a concentration 
of 200 nM in combination with the qPCR core kit. Reactions were run on 
a sequence detection system (GeneAmp 7300; Applied Biosystems) in tripli-
cates, and expression values were normalized to -actin or HPRT/ubiquitin 
expression using the comparative Ct method. Primers were purchased from 
Eurofins MWG Operon and, whenever possible, were designed to span at 
least one intron. Probes were purchased from Eurogentec.
Generation of radiation BM chimeras
4–5-wk-old recipients were lethally irradiated (8.5–9.5 Gy) and reconsti-
tuted within 24 h with TC-depleted BM (5 × 106 cells/animal). Functional 
analysis of antigen presentation and phenotype analysis of grafted animals was 
performed after another 5–8 wk.
Ex vivo proliferation assay
Purified  TSCs  were  co-cultured  with  naive  transgenic  OVA-specific 
(DO11.10; Murphy et al., 1990) or P1A-specific (TCR-P1Atg; Shanker et 
al., 2004) TCs, or PLP-specific TC lines (TPLP15-5-2; Klein et al., 2000), 
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the Peptide-Synthesis Core Facility of the German Cancer Research Center). 
Antigen-specific proliferation was measured by incorporation of 3H[TdR], 
which was added for an additional 16–20 h of culture (1 µCi/well).
Statistics
The Wilcoxon exact sum-rank test was used for statistical analysis. Calcula-
tions were performed using SAS software (version 9.1; SAS Institute Inc.).
Online supplemental material
Fig. S1 shows a comparison of the capacity of mTECs and DCs from thymus 
and peripheral lymphoid organs of different mouse strains to present exoge-
nous peptides. Fig. S2 shows the presentation of endogenous and exogenous 
OVA by CD8+ and CD8 DC subpopulations from thymus and spleen. 
Fig. S3 shows the presentation of endogenous and exogenous P1A by CD-
80high and CD80low mTEC subsets in comparison to thymic and splenic DCs. 
Fig. S4 shows phenotype analysis of thymic DCs based on differential CD11c 
and EpCAM expression. Online supplemental material is available at http://
www.jem.org/cgi/content/full/jem.20082449/DC1.
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